AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...
Only a handful of major JRPGs get the anime treatment, and whether they’re actually any good tends to be a complete toss-up, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback